C - Chemistry – Metallurgy – 07 – K
Patent
C - Chemistry, Metallurgy
07
K
C07K 14/745 (2006.01) C12N 9/64 (2006.01) A61K 38/00 (2006.01)
Patent
CA 2502162
The present invention relates to novel Factor VII or VIIa variants comprising a substitution in at least one position selected from the group consisting of L39, 142, S43, K62, L65, F71, E82 and F275, which are positions involved in tissue factor binding. Such variants exhibit increased clotting activity as compared to human wild-type Factor VIIa. The present invention also relates to use of such Factor VII or VIIa variants in therapy, in particular for the treatment of a variety of coagulation-related disorders.
La présente invention concerne de nouveaux variants du facteur VII ou VIIa qui comprennent une substitution dans au moins une position sélectionnée dans le groupe formé par: L39, 142, S43, K62, L65, F71, E82 et F275. Ces variants présentent une activité de coagulation accrue comparativement au facteur VIIa de type sauvage humain. La présente invention se rapporte également à l'utilisation de ces variants du facteur VII ou VIIa, en thérapie, notamment pour le traitement de divers troubles liés à la coagulation.
Andersen Kim Vilbour
Haaning Jesper Mortensen
Maxygen Holdings Ltd.
Mbm Intellectual Property Law Llp
LandOfFree
Fvii or fviia variants having increased clotting activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fvii or fviia variants having increased clotting activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fvii or fviia variants having increased clotting activity will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1419054